Phase 4
N=30
Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)
Angle-closure Glaucoma
Bottom Line
View on ClinicalTrials.gov: NCT00762645 ↗Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Mar 2010
Primary outcome: Primary: Mean Intraocular Pressure (IOP) — 15.77; 18.35 millimeters mercury (mm Hg)
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Travoprost 0.004% (Travatan) (Drug); Pilocarpine 1% (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Alcon Research
- Primary completion
- May 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Intraocular Pressure (IOP) |
15.77; 18.35 | — |
| SECONDARY Number of Patients With Peripheral Anterior Synechiae (PAS) |
0; 0 | — |
Summary
The purpose of this study is to demonstrate that the Intraocular Pressure (IOP) lowering efficacy of Travoprost Ophthalmic Solution 0.004% is superior to that of Pilocarpine 1% in patients with chronic angle-closure glaucoma (CACG).
Eligibility Criteria
Inclusion Criteria
- Age ≥ 18 years
- Chronic Angle Closure Glaucoma (CACG)
- 21-35 millimeters mercury mean intraocular pressure on Eligibility visit day at 9 AM
- Peripheral iridotomy performed ≥ 1 Month prior to the Screening visit
- Anterior chamber angle in which the trabecular meshwork is not visible for ≥180 degrees in gonioscopy without indentation
- Peripheral anterior synechiae (PAS)
Exclusion Criteria
- Traumatic damage of the anterior chamber angle
- History of ocular inflammation or surgery (except for iridotomy) ≤ 3 months
- Patients who cannot be safely discontinued from use of all ocular hypotensive medication(s) for 12 days to 14 weeks
- Visual Acuity ≥ 1.0
- Contact lenses wearer
Data sourced from ClinicalTrials.gov (NCT00762645). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.